Last reviewed · How we verify
Vasexten (BARNIDIPINE)
Vasexten (generic name: BARNIDIPINE) is a barnidipine drug. It is currently in Phase 2 development.
Vasexten works by blocking calcium channels in the heart and blood vessels, which helps to relax and widen blood vessels, reducing blood pressure.
Vasexten, also known as BARNIDIPINE, is a small molecule drug that targets voltage-gated L-type calcium channels. It is classified as a barnidipine drug class and is used to treat certain cardiovascular conditions. The commercial status of Vasexten is unclear, as it is not FDA-approved and its patent status is unknown. Key safety considerations include its low bioavailability of 1%. Vasexten is developed by an unknown original developer and is currently owned by an unknown entity.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BARNIDIPINE |
|---|---|
| Drug class | barnidipine |
| Target | Voltage-gated L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Imagine your blood vessels are like roads in your body. When you have high blood pressure, the roads get congested and narrow. Vasexten helps to relax the muscles around the roads, making them wider and allowing blood to flow more easily. This helps to lower blood pressure and reduce the risk of heart disease.
Approved indications
Common side effects
- Drug interaction
- Hypertensive crisis
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- The Efficacy, Safety and Genetic Polymorphism of Hypoca and Adalat OROS in Hypertensive Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vasexten CI brief — competitive landscape report
- Vasexten updates RSS · CI watch RSS
Frequently asked questions about Vasexten
What is Vasexten?
How does Vasexten work?
What is the generic name of Vasexten?
What drug class is Vasexten in?
What development phase is Vasexten in?
What are the side effects of Vasexten?
What does Vasexten target?
Related
- Drug class: All barnidipine drugs
- Target: All drugs targeting Voltage-gated L-type calcium channel
- Therapeutic area: All drugs in Cardiovascular
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing